Table 2.
Comparison of univariate outcomes of patients who underwent first allogeneic transplant with an HLA-identical sibling donor or an unrelated donor for AML in CR1 and received preparation with Cy/TBI, oral or IV BuCy, reported to the CIBMTR between 2000 and 2006
| Outcomes | Cy/TBI Probability (95% CI) | Oral BuCy Probability (95% CI) | IV BuCy Probability (95% CI) | P values (Pointwise) |
|---|---|---|---|---|
| Neutrophil engraftment | ||||
| NEval | 585 | 407 | 236 | |
| at 28 d | 95 (89-98) | 93 (86-97) | 95 (85-100) | .824 |
| at 100 d | 98 (90-100) | 99 (87-100) | 97 (85-100) | .964 |
| Platelet engraftment | ||||
| NEval | 582 | 390 | 234 | |
| at 28 d | 62 (58-67) | 73 (67-79) | 67 (60-74) | .012 |
| at 100 d | 88 (83-93) | 92 (85-97) | 91 (81-97) | .625 |
| Acute GVHD (grade II-IV) | ||||
| NEval | 584 | 408 | 236 | |
| at 100 d | 51 (47-55) | 39 (34-44) | 40 (33-46) | <.001 |
| Acute GVHD (grade III-IV) | ||||
| NEval | 586 | 408 | 236 | |
| at 100 d | 25 (21-28) | 14 (11-18) | 17 (13-22) | <.001 |
| Chronic GVHD | ||||
| NEval | 572 | 401 | 229 | |
| at 1 y | 44 (39-49) | 42 (36-47) | 49 (41-57) | .303 |
| at 5 y | 52 (47-57) | 48 (42-53) | 55 (46-63) | .314 |
| NRM | ||||
| NEval | 586 | 407 | 236 | |
| at 1 y | 21 (17-24) | 14 (10-17) | 12 (8-17) | .002 |
| at 5 y | 31 (27-35) | 18 (14-22) | 18 (13-24) | <.001 |
| Progression/relapse | ||||
| NEval | 586 | 407 | 236 | |
| at 1 y | 20 (17-24) | 16 (13-20) | 23 (17-28) | .155 |
| at 5 y | 28 (24-32) | 27 (23-32) | 25 (19-31) | .726 |
| LFS | ||||
| NEval | 586 | 407 | 236 | <.001* |
| at 1 y | 59 (55-63) | 70 (65-75) | 65 (59-72) | .002 |
| at 5 y | 41 (37-46) | 54 (49-60) | 57 (50-64) | <.001 |
| Overall survival | ||||
| NEval | 586 | 408 | 236 | <.001* |
| at 1 y | 65 (61-68) | 76 (71-80) | 72 (66-78) | <.001 |
| at 5 y | 43 (39-47) | 61 (56-66) | 58 (51-65) | <.001 |
NEval, number evaluated.
*
Log-rank test P value.